reports
Oncolytics Biotech Inc: 4 directors
Four Directors at Oncolytics Biotech Inc bought 72,774 shares at between 0.835USD and 0.861USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
Oncolytics Biotech® Announces First Patient Treated in Study Combinin...
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients. This...
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as C...
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as Chief Medical Officer. Dr. Laeufle will oversee the clinical development plan for pelareorep as the company drives towards a registration study in bre...
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study ...
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 2 study combining pelareorep with Merck’s Keytruda® to treat advanced pancreatic adenocarcinoma. The primary objective of the study is to determine the overall response rate (ORR) by iRECIST criter...
Oncolytics Biotech® Announces Attendance of Upcoming Conferences
Oncolytics Biotech® Announces Attendance of Upcoming Conferences CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the Company is scheduled to attend the following upcoming conferences: Jefferies 2018 London Healthcare Conference November 14 & 15, 2018, Waldorf Hilton, London, UK Dr. Matt Coffey, President & CEO and Mr. Kirk Look, CFO, to attend and host meetings 60th Annual American Society of Hematology Annual M...
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and...
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update - Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference call today at 8:30 a.m. ET - CALGARY, Alberta and SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced financial results and operational highlights for the quart...
Oncolytics Biotech® Announces Presentation at the Society for Immunot...
Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection - Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that data will be presented demonstrating pelareorep’s ability to upregulate PD-L1 during infection of prostate canc...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter ...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights CALGARY, Alberta and SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Monday, November 12, 2018 following release of its third quarter 2018 financial results. The live call may be accessed by dialing (888) 231-8191 fo...
Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Expos...
Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor Pelareorep ideal candidate for combination with immune checkpoint inhibitors CALGARY, Alberta and SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced publication of an abstract on pelareorep to be presented at the American Society of Hematology (ASH) Annual Meeting & Exposition t...
Oncolytics Biotech® Establishes New At-The-Market Facility
Oncolytics Biotech® Establishes New At-The-Market Facility CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus that turns cold tumors hot, today announced that it entered into an At-the-Market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to $30 million over the ...
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pel...
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018 - Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced positive clinical trial results for pelareorep in the treatment of ...
Oncolytics Biotech® Announces Publication of Positive Clinical Result...
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress - Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data - CALGARY, Alberta and SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of an abstract on pelareorep (formerly known as REOLYSIN) for the European Society for ...
Oncolytics Biotech® Announces a Publication Demonstrating That Intrav...
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of important research in the peer-reviewed journal Cancer Immunology Research. The research showed that pelareorep, a systemically delivered oncolytic reovirus, c...
Oncolytics Biotech® Enters into Common Stock Purchase Agreement for u...
Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC CALGARY, Alberta and SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY), (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the execution of a Common Stock Purchase Agreement (“Agreement”) for up to US$26.0 million with Lincoln Park Capital Fund, LLC ("LPC"), an institutional investor. Upon signing of the Agreement, dated September 27, 2018, LPC initial...
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthc...
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference CALGARY, Alberta and SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 3:30 pm ET, on Tuesday, October 2, 2018 in the Montmartre Room at the Sofitel Hotel in New York City. A ...
Oncolytics Biotech® Provides Corporate and Clinical Update
Oncolytics Biotech® Provides Corporate and Clinical Update - Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a corporate update would be provided in a conference call and webcast covering both business and clinical development activities. Management will host a webcast and conference call on Thursda...
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma...
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a second study in multiple myeloma. This study will combine pelareorep and nivolumab (Opdivo®) with standard of care for patients with relapsed/refractory multiple myeloma. Pomalyst®, an immunomodu...
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Op...
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep CALGARY, Alberta and SAN DIEGO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. This clinical collaboration, being sponsored by Oncolytics and facilitated by SOLTI...
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of a...
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the company’s clinical development pro...
Oncolytics Biotech® Reports 2018 Second Quarter Results
Oncolytics Biotech® Reports 2018 Second Quarter Results CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and operational highlights for the quarter ended June 30, 2018. All dollar amounts are Canadian unless otherwise noted. “The second quarter began with clinical updates at three scientific conferences and an agreement with the FDA for our Special Protocol Assessment...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.